A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

NCT04899271 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped low recruitment rate

Conditions

New-onset Type 1 Diabetes

Interventions

DRUG: Ladarixin
OTHER: Placebo

Sponsor

Dompé Farmaceutici S.p.A